MyFinsight
Home
Blog
About
Cash and cash
equivalents
$43,287K
(18.62%↑ Y/Y)
Accounts receivables,
net
$27,760K
(12.71%↑ Y/Y)
Short-term investment
$17,451K
Short-term bank deposits
$14,058K
(-21.35%↓ Y/Y)
Inventories, net
$11,428K
(28.97%↑ Y/Y)
Prepaid assets and other
current assets
$7,601K
(181.41%↑ Y/Y)
Other receivables
from gni
$255K
(10.87%↑ Y/Y)
Notes receivable
$232K
(-53.51%↓ Y/Y)
Property and equipment,
gross
$39,984K
(34.06%↑ Y/Y)
Gross carrying amount
$5,938K
Total current assets
$122,072K
(33.73%↑ Y/Y)
Long-term certificates of
deposit
$28,444K
(32.13%↑ Y/Y)
Property and equipment,
net
$27,284K
(16.59%↑ Y/Y)
Deferred tax assets
$9,284K
(51.35%↑ Y/Y)
Other assets,
noncurrent
$7,344K
(37.63%↑ Y/Y)
Intangible assets, net
$4,525K
(-8.81%↓ Y/Y)
Long-term prepayments
$302K
Less accumulated
depreciation
$12,700K
(97.67%↑ Y/Y)
Accumulated amortization
$1,413K
Total assets
$199,255K
(30.53%↑ Y/Y)
Total liabilities,
series b preferred...
$199,255K
(30.53%↑ Y/Y)
Total equity
$142,489K
(10.08%↑ Y/Y)
Total liabilities
$34,336K
(47.98%↑ Y/Y)
Temporary equity,
carrying amount-Series...
$22,430K
Total gyre
stockholders' equity
$107,928K
(17.28%↑ Y/Y)
Noncontrolling interest
$34,561K
(-7.63%↓ Y/Y)
Total current
liabilities
$28,663K
(69.40%↑ Y/Y)
Warrant liability,
noncurrent
$2,741K
(-14.37%↓ Y/Y)
Operating lease
liabilities, noncurrent
$2,033K
(163.68%↑ Y/Y)
Deferred government
grants
$829K
(-6.22%↓ Y/Y)
Other noncurrent
liabilities
$70K
(-95.09%↓ Y/Y)
Accumulated deficit
-$137,962K
(-96.21%↓ Y/Y)
Additional paid-in capital
$240,644K
(49.06%↑ Y/Y)
Accrued expenses and
other current...
$18,810K
(26.04%↑ Y/Y)
Due to related
parties
$5,085K
(2221.92%↑ Y/Y)
Income tax payable
$2,147K
(98.06%↑ Y/Y)
Operating lease
liabilities, current
$1,385K
(122.67%↑ Y/Y)
Accounts payable
$1,236K
(1640.85%↑ Y/Y)
Statutory reserve
$3,648K
(17.75%↑ Y/Y)
Accumulated other
comprehensive income (loss)
$1,492K
(165.24%↑ Y/Y)
Common stock, 0.001 par
value, 400,000,000...
$106K
(16.48%↑ Y/Y)
Back
Back
Balance Sheet
GYRE THERAPEUTICS, INC. (GYRE)
GYRE THERAPEUTICS, INC. (GYRE)
source: myfinsight.com